IVALTINOSTAT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H33N3O4
Molecular Weight	427.5365
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of IVALTINOSTAT

Structure Search

SMILES

CN(C)CCCNC(=O)C(\COC1=C2C=CC=CC2=CC=C1)=C\CCCCC(=O)NO

InChI

InChIKey=AUGCSOFQTDKPSO-RGVLZGJSSA-N

InChI=1S/C24H33N3O4/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28)/b20-11+

HIDE SMILES / InChI

Molecular Formula	C24H33N3O4
Molecular Weight	427.5365
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21042746 | https://www.ncbi.nlm.nih.gov/pubmed/21773733

CG-200745 is a novel inhibitor of histone deacetylases (HDACs), initially developed by CrystalGenomics, Inc for treatment of various hematological and solid cancers. Combinations of CG-200745 with SN38 (the active form of irinotecan), or oxaliplatin were more effective than the agents alone when used to inhibit the growth of HCT116 cells. The protein expressions of acetyl-H3, p21, caspase-3, -8, and -9, PARP, and XIAP were affected in a time- and dose-dependent manner in HCT116 cells treated with the CG-200745 alone or combined CG-200745 and SN-38. In HCT116 xenografts, the HDACI CG-200745 in combination with irinotecan dramatically inhibited tumor growth without showing additive toxicity.

Originator

Approval Year

PubMed

PubMed

Title	Date	PubMed

Patents

Patents

Sample Use Guides

In Vivo Use Guide

mice 30 mg/kg, 5 days/week

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:09:17 GMT 2023` Edited by `admin` on `Sat Dec 16 11:09:17 GMT 2023`
Record UNII	4I8MLM7L2H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IVALTINOSTAT

Official Name

English

CG-200745

Preferred Name

English

CG 2 (HDAC INHIBITOR)

Code

English

CG-2

Code

English

ivaltinostat [INN]

Common Name

English

CG200745

Code

English

HDCG-0745

Code

English

2-OCTENEDIAMIDE, N1-(3-(DIMETHYLAMINO)PROPYL)-N8-HYDROXY-2-((1-NAPHTHALENYLOXY)METHYL)-, (2E)-

Systematic Name

English

J3.106.463E

Code

English

(E)-N-(3-(DIMETHYLAMINO)PROPYL)-N'-HYDROXY-2-((1-NAPHTHYLOXY)METHYL)-2-OCTENEDIAMIDE

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

919022

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

FDA ORPHAN DRUG

760420

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

FDA ORPHAN DRUG

846121

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

FDA ORPHAN DRUG

793520

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

Code System Code Type Description

EPA CompTox

DTXSID801028069

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

SMS_ID

300000010881

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

PUBCHEM

16117309

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

CAS

936221-33-9

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

CG-200745

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

Description: CG200745 is a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI). Like other inhibitors, CG200745 has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG200745 inhibited deacetylation of histone H3 and tubulin as much as vorinostat and belinostat did. CG200745 also inhibited growth of prostate cancer cells, increased sub-G1 population, and activated caspase-9, -3 and -8 in LNCaP, DU145 and PC3 cells. These results indicate that CG200745 induces apoptosis. The preclinical results show that combination treatment with docetaxel and new HDACI, CG200745, potentiated anti-tumor effect in hormone-refractory prostate cancer (HRPC) cells via activation of apoptosis. (Last update: 5/30/2016).

CLINICAL_TRIALS.GOV

HDCG-0745

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

Official Title: A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer.The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m^2, and it will be extended to 250 mg/m^2, 312.5 mg/m^2 or it will be reduced to 125 mg/m^2 based on the results of the cohort of 3 subjects per dose level.In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.

DRUG BANK

DB12259

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

INN

11072

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

CLINICAL_TRIALS.GOV

CG-200745

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

Official Title: A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy

NCI_THESAURUS

C94225

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

FDA UNII

4I8MLM7L2H

Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023

PRIMARY

Related Record Type Details


					O037NFL7YQ

HISTONE DEACETYLASE 1

TARGET -> INHIBITOR


					QA3Y8EZG57

IVALTINOSTAT PHOSPHATE

SALT/SOLVATE -> PARENT

Amount:


					KJ1F8SDB3A

HISTONE DEACETYLASE 4

TARGET -> INHIBITOR


					X6HV7Q6XP4

HISTONE DEACETYLASE 6

TARGET -> INHIBITOR


					7YNS2RVD5Q

HISTONE DEACETYLASE 3

TARGET -> INHIBITOR


					RV2QAE6UDF

HISTONE DEACETYLASE 2

TARGET -> INHIBITOR

Related Record Type Details


					4I8MLM7L2H

ACTIVE MOIETY

Comments:

Originator: CrystalGenomics; Class: Antineoplastic; Mechanism of Action: Histone deacetylase inhibitor; Highest Development Phases: Phase II for Cancer, Phase I/II for Pancreatic cancer; Most Recent Events: 08 Apr 2016 CrystalGenomics plans a phase I/II trial for Myelodysplastic syndrome (Second-line therapy or greater) in South Korea (IV) (NCT02737462), 01 Mar 2016 Phase-I/II clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Inoperable/Unresectable, Late-stage disease, First-line therapy) in South Korea (IV) (NCT02737228), 11 Feb 2016 Phase-II development is ongoing in South Korea